JPS6129952B2 - - Google Patents
Info
- Publication number
- JPS6129952B2 JPS6129952B2 JP50154665A JP15466575A JPS6129952B2 JP S6129952 B2 JPS6129952 B2 JP S6129952B2 JP 50154665 A JP50154665 A JP 50154665A JP 15466575 A JP15466575 A JP 15466575A JP S6129952 B2 JPS6129952 B2 JP S6129952B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- dianhydro
- dulcitol
- dad
- hydrogen atom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000001875 compounds Chemical class 0.000 claims description 8
- 125000002252 acyl group Chemical group 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 150000008065 acid anhydrides Chemical class 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 1
- 230000010933 acylation Effects 0.000 claims 1
- 238000005917 acylation reaction Methods 0.000 claims 1
- 125000003435 aroyl group Chemical group 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 150000004820 halides Chemical class 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- AAFJXZWCNVJTMK-GUCUJZIJSA-N (1s,2r)-1-[(2s)-oxiran-2-yl]-2-[(2r)-oxiran-2-yl]ethane-1,2-diol Chemical group C([C@@H]1[C@H](O)[C@H](O)[C@H]2OC2)O1 AAFJXZWCNVJTMK-GUCUJZIJSA-N 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 238000011282 treatment Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000001085 cytostatic effect Effects 0.000 description 3
- 150000002924 oxiranes Chemical class 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- TZQPAZWGRJYTLN-KVTDHHQDSA-N (2r,3r,4r,5r)-hexane-2,3,4,5-tetrol Chemical compound C[C@@H](O)[C@@H](O)[C@H](O)[C@@H](C)O TZQPAZWGRJYTLN-KVTDHHQDSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- -1 L-1 Chemical class 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/16—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by esterified hydroxyl radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/14—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by free hydroxyl radicals
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epoxy Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU74MA00002630A HU172826B (hu) | 1974-12-24 | 1974-12-24 | Sposob poluchenija novykh acilnykh proizvodnykh 1,2-5,6-diangidro-geksitov s protivoopukholevoj aktivnost'ju |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS51125201A JPS51125201A (en) | 1976-11-01 |
| JPS6129952B2 true JPS6129952B2 (is) | 1986-07-10 |
Family
ID=10998754
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP50154665A Granted JPS51125201A (en) | 1974-12-24 | 1975-12-24 | Antitumor compound |
Country Status (17)
| Country | Link |
|---|---|
| JP (1) | JPS51125201A (is) |
| AT (1) | AT345303B (is) |
| BE (1) | BE837054A (is) |
| CH (1) | CH620208A5 (is) |
| CS (1) | CS220403B1 (is) |
| DD (1) | DD124803A1 (is) |
| DE (1) | DE2557033C2 (is) |
| DK (1) | DK156271C (is) |
| FI (1) | FI61187C (is) |
| FR (1) | FR2295743A1 (is) |
| GB (1) | GB1490649A (is) |
| HU (1) | HU172826B (is) |
| NL (1) | NL7514991A (is) |
| NO (1) | NO144632C (is) |
| PL (1) | PL101458B1 (is) |
| SU (1) | SU581860A3 (is) |
| YU (1) | YU40449B (is) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0228032A (ja) * | 1988-07-14 | 1990-01-30 | Suzuki Motor Co Ltd | 自動車 |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU182227B (en) * | 1980-11-04 | 1983-12-28 | Chinoin Gyogyszer Es Vegyeszet | Process for preparing hexitols containing free carboxyl group |
| HU195754B (en) * | 1984-01-18 | 1988-07-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing 1,2-5,6-dianhydro-3,4-diacyl-dulcitol |
| US9901563B2 (en) | 2013-03-11 | 2018-02-27 | Delmar Pharmaceuticals, Inc. | Compositions to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dianhydrogalactitol and diacetyldianhydrogalactitol |
| AU2011292044A1 (en) * | 2010-08-18 | 2013-04-04 | Del Mar Pharmaceuticals | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dianhydrogalactitol and diacetyldianhydrogalactitol |
-
1974
- 1974-12-24 HU HU74MA00002630A patent/HU172826B/hu not_active IP Right Cessation
-
1975
- 1975-12-18 DE DE2557033A patent/DE2557033C2/de not_active Expired
- 1975-12-19 AT AT966175A patent/AT345303B/de not_active IP Right Cessation
- 1975-12-22 FR FR7539338A patent/FR2295743A1/fr active Granted
- 1975-12-23 YU YU3269/75A patent/YU40449B/xx unknown
- 1975-12-23 CH CH1673675A patent/CH620208A5/de not_active IP Right Cessation
- 1975-12-23 CS CS758837A patent/CS220403B1/cs unknown
- 1975-12-23 DD DD190504A patent/DD124803A1/xx not_active IP Right Cessation
- 1975-12-23 NL NL7514991A patent/NL7514991A/xx not_active Application Discontinuation
- 1975-12-23 PL PL1975185921A patent/PL101458B1/pl unknown
- 1975-12-23 NO NO754374A patent/NO144632C/no unknown
- 1975-12-23 FI FI753643A patent/FI61187C/fi not_active IP Right Cessation
- 1975-12-23 GB GB52713/75A patent/GB1490649A/en not_active Expired
- 1975-12-23 DK DK589775A patent/DK156271C/da not_active IP Right Cessation
- 1975-12-24 SU SU7502302301A patent/SU581860A3/ru active
- 1975-12-24 JP JP50154665A patent/JPS51125201A/ja active Granted
- 1975-12-24 BE BE163090A patent/BE837054A/xx not_active IP Right Cessation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0228032A (ja) * | 1988-07-14 | 1990-01-30 | Suzuki Motor Co Ltd | 自動車 |
Also Published As
| Publication number | Publication date |
|---|---|
| PL101458B1 (pl) | 1978-12-30 |
| CS220403B1 (en) | 1983-04-29 |
| YU40449B (en) | 1986-02-28 |
| FR2295743B1 (is) | 1978-11-10 |
| BE837054A (fr) | 1976-04-16 |
| ATA966175A (de) | 1978-01-15 |
| DK156271B (da) | 1989-07-24 |
| GB1490649A (en) | 1977-11-02 |
| NL7514991A (nl) | 1976-06-28 |
| DK156271C (da) | 1989-12-11 |
| JPS51125201A (en) | 1976-11-01 |
| SU581860A3 (ru) | 1977-11-25 |
| DE2557033C2 (de) | 1983-12-22 |
| NO144632C (no) | 1981-10-07 |
| FR2295743A1 (fr) | 1976-07-23 |
| HU172826B (hu) | 1978-12-28 |
| NO144632B (no) | 1981-06-29 |
| DE2557033A1 (de) | 1976-07-22 |
| DK589775A (da) | 1976-06-25 |
| FI61187B (fi) | 1982-02-26 |
| YU326975A (en) | 1982-02-28 |
| CH620208A5 (en) | 1980-11-14 |
| NO754374L (is) | 1976-06-25 |
| FI61187C (fi) | 1982-06-10 |
| AT345303B (de) | 1978-09-11 |
| DD124803A1 (is) | 1977-03-16 |
| FI753643A (is) | 1976-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6306893B1 (en) | Taxoid derivatives and process for producing the same | |
| US5681847A (en) | Methods of using discodermolide compounds | |
| CN1130356C (zh) | 具有抗肿瘤活性的半合成断紫杉烷 | |
| WO1997020835A9 (en) | Discodermolide compounds and pharmaceutical compositions containing them for cancer therapy | |
| US4031211A (en) | Adriamycin esters, their preparation and use | |
| JPS6129952B2 (is) | ||
| KR970702725A (ko) | 비소세포 폐암 치료용 의약 조성물(Medicinal Composition as a Remedy for Nonsmall Cell Lung Cancer) | |
| JPH0142275B2 (is) | ||
| RU95110110A (ru) | Производные бензофурана, способ их получения, фармкомпозиция и способ лечения | |
| SK139994A3 (en) | Taxane derivatives, their preparation and compositions containing same | |
| WO1999052888A1 (en) | Butenolide derivatives as anti-cancer agents | |
| GB981046A (en) | Hexahydro-4ah-8,9c-iminoethano phenanthro-[4,5-b,c,d]-furan derivatives | |
| CA1123740A (en) | Therapeutic compositions with a cytostatic action and method | |
| US4232149A (en) | 1-(5-Fluoruracil-1)-2,5-di-O-acetyl-β-D-glucofuranurono-6,3-lactone | |
| EP1946758A1 (en) | Treatment of acute myeloid leukemia | |
| US2451772A (en) | Solubilization of rutin with methyl glucamine | |
| WO1998049174A1 (en) | Synthesis of platinum complexes and uses thereof | |
| JPH0114238B2 (is) | ||
| JPS6260393B2 (is) | ||
| US4824944A (en) | Antineoplastic enamine derivatives of daunorubicin and adriamycin | |
| CN115197113B (zh) | 含硫脲结构的Combretastatin A-4衍生物、其制备方法及其用途 | |
| CN110713505B (zh) | 一种γ-内酰胺糖苷类衍生物及其合成方法与应用 | |
| FR2723372A1 (fr) | Nouveaux derives de streptogramine, leur preparation et les compositions pharmaceutiques qui les contiennent | |
| FR2668152A1 (fr) | Derives n,o spirocycliques de cyclotriphosphazenes, leur preparation et leur application en therapeutique. | |
| SE449105B (sv) | 13-/1-oxyl-2,2,6,6-tetrametylpiperyldenyl-4/-rubomycinhydrazon hydroklorid samt forfarande for dess framstellning |